Trial Profile
Intranasal Vasopressin Treatment in Children With Autism
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Vasopressin (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 20 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2021 Protocol amended to change study phase from II to II/III and masking changed from open to double blinding.
- 10 Feb 2021 Planned End Date changed from 1 Feb 2023 to 1 Jul 2024.